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Summnu.a The strategy of combining carbogen breathing and nicotinamide to overcome chronic and acute
hypoxia respectively is being evaluated clinically. The effects of both agents individually and in combination
on relative perfusion of 400-700 mm3 RIF-I tumours and normal tissues were measured by 'Rb extraction.
Carbogen breathing alone for 6 min increased relative tumour perfusion by 50-700,<0 compared with control at
flow rates of 50 to 200 ml min- '. but the effect was lost at 300 ml min- '. All flow rates also produced similar
increases in relative perfusion of lung, of between 36% and 58%. and smaller increases in skin, of between
200 and 3400. The minimum breathing time at 150mlmin-' to produce a significant increase in relative
tumour perfusion was 4.5 min. and the effect was maintained up to 9 min. Nicotinamide alone at
1000mgkg-' 60min before assay did not alter relative tumour perfusion. Comparing the combination of
nicotinamide with 6 min carbogen breathing at 150 ml min- with carbogen breathing alone showed no
difference in relative tumour perfusion: increases were of 36% and 42% respectively. Nicotinamide-induced
alterations in microcirculation associated with reduction of acute hypoxia have therefore not been detected by
'Rb extraction. The perfusion-enhancing effect of carbogen in this tumour is probably an important
component of its radiosensitising ability. in addition to its known ability to increase the oxvgen-carrving
capacity of the blood. and should be taken into consideration in clinical studies.
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It has been generally accepted that hypoxia may be responsi-
ble for the failure of clinical radiotherapy, delivered in a
fractionated schedule. in some patients. Numerous strategies
to overcome this hypoxia have been studied. Relatively
recent evidence has supported the hypothesis that it can have
a major impact. Overgaard (1992) carried out a meta-analysis
of data from a wide range of climical tnrals on over 9000
patients and showed that strategies to overcome hypoxia
significantly improved both local control and survival. More
direct evidence comes from work correlating direct intra-
tumour oxygen tension measurements with response to
radiotherapy. This was first demonstrated in carcinoma of
the cervix (Kolstad, 1968). and interest in the technique has
been revived by more recent work in lymph node metastases
of the head and neck (Gatenby et al., 1988) with tumour
response as an end point, and in advanced primary car-
cinoma of the cervix (H6ckel et al., 1993) in which both
response and survival correlate with oxygenation status.
Current thinking in terms of methods of overcoming
hypoxia recognises the need to overcome both chronic
hypoxia, occurring in cells located further from a vessel than
the maximum distance for diffusion of oxygen, and acute
hypoxia, resulting from transient closure of capillaries.
Nicotinamide is an effective radiosensitiser of a wide variety
of experimental tumours (Horsman et al., 1987. 1989a,b;
Kjellen et al.. 1991: Chaplin et al.. 1991). thought to act by
enhancing tumour perfusion (Horsman et al.. 1989a), and it
has been shown in two tumour systems to act, at least in
part, by elimination of transient closure of vessels (Chaplin et
al.. 1990; Horsman et al.. 1990). It is considered to have
relatively low toxicity and is now being assessed clinically in
the dose range required to produce the plasma concentra-
tions which are effective radiosensitisers in model systems
(Horsman et al.. 1993; Rojas et al., 1993a). The possibility of
overcoming chronic hypoxia by breathing carbogen. a mix-
ture of 95% oxygen with 5% carbon dioxide, is also cur-
rently being reassessed. Previous clinical investigations of
carbogen flagged after a negative study (Rubin et al.. 1979)
and in the face of competition from the enormous surge of
interest in chemical oxygen-mimetic radiosensitisers in the
1970s. There is now interest in the possibility of combining
nicotinamide and carbogen with accelerated fractionation, a
strategy designed to increase the efficacy of radiation in
tumours with a short potential doubling time (Rojas, 1992).
Much of the evidence supporting these planned European
clinical trials is from work on direct measurement of
modification of radiocurability of murine tumours by
nicotinamide and carbogen (Kjellen et al.. 1991: Rojas. 1991;
Rojas et al.. 1993a,b). While there is some information for
nicotinamide as mentioned above (Horsman et al.. 1989a:
Chaplin et al.. 1990) and evidence for increased tumour
blood flow was noted in an early report on the effect of
carbogen (Kruuv, 1967), it is tacitly assumed that carbogen
acts primarily by increasing the oxygen-carrying capacity of
the blood.
The aim of this study was firstly to investigate the effects
of carbogen, at a range of flow rates and breathing times, on
relative RIF-I tumour and normal tissue perfusion to assess
whether changes in perfusion could potentially contribute to
the radiosensitising effect of carbogen. The second aim was
to investigate in the same systems the combination of car-
bogen breathing with nicotinamide, to compare the individ-
ual and combined effects of the agents. Normal tissues were
studied in addition to tumour to enable an assessment to be
made as to whether any changes were tumour specific or
secondary to changes in the supplying tissue, and also wheth-
er or not a treatment caused widespread imbalance of per-
fusion.
Materials and Methods
Tumour sistem
The RIF-1 tumour was maintained in tissue culture accord-
ing to the protocol of Twentyman (1980). Tumours were
initiated in female 10- to 16-week-old C3H mice of 24-30 g
by inoculation of 2-4 x 105 tumour cells subcutaneously in
the lower back, at the base of the tail. Tumour volume in
mm3 was approximated from xabc 6, where a, b and c are
three mutually perpendicular diameters of the shaved tumour
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m mm, measured with calipers by the same investigator in all
experiments. All experiments were carried out in compliance
with the UKCCCR (1988) guidelines on the welfare of
animals used in research, under Home Office project licence
numbers PPL 80/00085 and PPL 80/00845.
Nicotinamide treatment
Nicotinamide (Aldrich Chemicals) was prepared daily in
phosphate-buffered saline (PBS) at 100mgml-', and injected
intraperitoneally at 1000 mg kg-' 60 min before measurement
of relative perfusion. This 60 min exposure was selected since
optimum radiosensitisation of the RIF-1 tumour has been
reported to occur at times from 1 to 2.5 h after administra-
tion of this dose of nicotinamide (Horsman et al., 1987).
Carbogen treatment
Carbogen (95% oxygen, 5% carbon dioxide; from British
Oxygen) was administered individually to mice restrained in
a custom-built jig. The jig comprised a black Perspex tube
with a tumour access port at the rear through which the
tumour projected and a detachable rear gate through which
the tail was passed and gently taped down. The mid part of
the tube, behind the animal's head and in front of the
tumour port, had multiple perforations. Humidified car-
bogen, warmed to room temperature, was piped directly into
the anterior end of the jig, travelled past the animal's head,
out through the perforations and was collected in a clear
Perspex jacket which enclosed thejig from just in front ofthe
tumour port and ducted out of the building from this outer
tube. The flow rate was adjusted and monitored with a
combined regulator and direct-reading flow meter (GAP,
UK). By this technique the animal was provided with a
constant supply of fresh carbogen, flowing at a measured
rate, and all exhaled gases were immediately removed. The
volume of air or gas in front of the animal in the jig was
10± 1.5ml (±2s.e., n= 12), hence a flow rate of
150 ml min- was equivalent to 15 gas exchanges per minute.
This system mimics fairly closely the carbogen breathing
system typically used for clinical studies. Control animals and
those receiving nicotinamide alone were restrained in a
similar jig, but breathed air.
Measurement ofrelative tissueperfusion
This was measured by the method developed by Sapirstein
(1959) as previously described (Honess and Bleehen, 1993).
The animal remained in the jig, breathing carbogen or air,
and approximately 8 sCi of 'RbCG (Amersham, UK) was
injected i.v. via the tail vein in 0.lml and 60s later the
mouse was killed by cervical dislocation and tissues of
interest were rapidly excised (within 2 min), placed in
preweighed glass vials, weighed and counted on a Wallac
1282 gamma counter. Tails were also counted, injected
counts were individually corrected for residual activity in the
tail and the percentage of injected counts per gram wet
weight of tissue was calculated. Typically 10-12 mice were
used for each treatment group, and means and 95%
confidence limits were calculated and expressed as a percen-
tage of the mean for the control group. Experiments were
repeated at least once. Treated groups were compared with
the corresponding control group using an unpaired, two-
tailed t-test and where P<0.05 the difference was considered
to be significant.
Tumour temperature measurement
Central tumour temperatures were measured durng carbogen
or air breathing with a 3201p thermocouple probe associated
with a BAT-12 thermometer (Bailey Instruments, NJ, USA).
The temperature was noted as soon as the animal was
restrained in the jig and immiately before it was removed
before cervical dislocation.
Results
For animals breathing carbogen for 5 min before and during
the 1 min exposure to ssRbC1, the effect ofincreasing the flow
rate ofcarbogen over the animals is shown in Figure 1. Flow
rates of 50-200 ml min-' all increased relative tumour per-
fusion by between 50% and 70% compared with control
(Figure la), increases which are statistically significant
(P=0.001 for 50mlmin-' and P<10-3 for 100, 150 and
200 mlmin-' compared with conrol) but are not significantly
different from one another (P>0.5). At higher flow rates the
increase in perfusion was smaller, with an increase of 24%
after 250 ml min-' (P = 0.01) and a small increase which was
not significant after 300mlmin-' (12%, P=0.24).
In skin and lung significant increases in tissue perfusion
(P< 10-3) were observed at all flow rates (Figure la and b),
with less variation between individual animals than was
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Fugwe I Relative RIF-l tumour and normal tissue perfusion
after breathing carbogn for 5 min before and during exposure to
'RbCI, i.e. for a total of 6 min, at a range of flow rates.
Breathing at 150 ml min-' is equivalent to 15 gas exchanges per
min. (a) Data for tumour (0) and skin (A), (b) data for lung
(0) and muscle (A) and (c) data for spleen (-), kidney (0) and
liver (V). Data are pooled from two separate experiments;
n = 21-26. Bars show ± 95% CL and the hatched area shows the
range of ±95% CL for control animals for tumour (a), lung (b)
and kidney (c). Mean tumour volume (±s.d.) was
395 ± 85 mm3.
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Al_observed for tumours. Increases for lung ranged from 36%
after 300 mlmin-' to 58°% after 150 mlmin-', while those
for skin were rather smaller, ranging from 20% to 34%. The
effect -of carbogen breathing on muscle perfusion in these
experiments was to reduce relative perfusion to between 80%
and 88% of control at 150 to 250 ml min-' (P<l0-3,
P=0.016) to a certain extent balancing the effect in skin.
T1he effects on relative perfusion of the spleen, kidney and
liver are shown in Figure Ic and were much less marked than
in the other tissues measured and did not suggest a consistent
change in any of these organs, no change being greater than
20%. Nonetheless, there were significant changes in perfusion
of liver at 50 and l50ml min-', in kidney at l50 ml min-'
and in spleen at 250 and 300mlmin-' (P<0.05).
A flow rate of 150 ml min-' was selected for further work
since it was intermediate among those rates causing a sub-
stantial increase in tumour perfuision. Data for experiments
exploring the influence of carbogen breathing time at a con-
stant flow rate of 150 ml min-' are shown in Figure 2. Data
are plotted for the total breathing time; 'RbCI was
administered 1 min before the end of this. The results for
tumour indicate no measurable difference at 2.5min, but
significant increases after 4.5, 6 and 9min (P = 0.001,
P<10-3 and P=0.003 respectively) with a peak at 6min
with an increase by 94%, suggesting an optimum time of
6min. However, a further experiment (n= 11-13, not illus-
trated) comparing 6 min with 11 min showed increases of
40% and 61% respectively, with no significant difference
between the exposures, so there is no firm indication of a
deline in effect between 6 and 11 min, but it is clear that at
least 4.5 min breathing is required at 150 ml min-' to achieve
an increase. It is again clear from the data in Figure 2, as
with those in Figure 1, that the inter-animal variation is
greater in tumour than in normal tissues. Relative skin per-
fusion increased by 32% and 31a% after 6 and 9min respec-
tively (P = 0.001) and relative lung perfusion was elevated
under all conditions tested, by 32-53% (P<0.002). Muscle
perfusion changes were not significant in these experiments,
and there were no large changes in perfusion of splen, liver
and kidney, although perfusion for all these organs was
signifiantly reduced at 2.5 min (P<0.02).
A total breathing time of 6 min at 150mlmin-' was
selected for combination with nicotinamide treatment, and
relative perfusion was measured 60min after nicotinamide
administration. Mice not breathing carbogen also spent
6 min in the appropriate jig. Data are presented in Figure 3
and shdw that in tumour there was no effect of nicotinamide
alone, but that carbogen and the combination both produced
substantial increases, 42% and 36% rspectively (P<10-),
but the effects of both treatments were essentially the same.
The data in Figure 3 are pooled for two experiments with
rather different sized tumours (see klgend), but a further
experiment comparing the effect of carbogen in tumours of
both sizes showed that the increase was not dependent on
tumour size within this range; increases (±95% CL) were
66 ± 34% for tumours of 400-500 mm3 and 87 ± 16% for
those of 550-700mm3 (n = 9-1). There was no major
change in relative skin perfusion after any treatment. The
substantial carbogen-induced increase in relative perfusion of
lung, by 34% in these experiments, was abrogated by the
presence of nicotinamide, although nicotinamide alone had
no effect. Nicotinamide alone and in conjunction with car-
bogen produced large increases in relative spleen perfusion,
70% and 46% respectively. However, the effect of carbogen
on spleen perfusion and the effects of all three treatments on
kidney and liver perfusion were relatively small.
Central tumour temperatures nmasured immediately after
animals were restrained are presented in Table I and indicate
that tumours in nicotinamide-treated animals were approx-
imately 2-C cooler than in untreated animals. This
temperature drop is consistent with the drop in core
temperature experienced by nicotinamide-treated animals
(Horsman et al., 1989a). Carbogen breathing did not affect
tumour temperature. The data for temperature change dunng
time in the jig show that there were small variations but that
PoI~u chnp -f cwt mdamnd
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these were essentially random, and there was no consistent
pattern for any treatment; there is no significant difference
between any of the groups.
This study shows that carbogen breathing substantially in-
creased the perfusion of the RIF-I tumour, and it is likely
that this would contribute to an increase in radiosensitivity.
The findings are in agreement with those for the C3HBA
mammary carcinoma examined by Kruuv et al. (1967), also
located subcutaneously on the back, in which increased
blood flow was deduced indirectly from changes in
temperature of the skin overlying the tumour relative to that
of the rectum, indicating the core temperature. They contrast
a
250
.225
46 2
_ 175w
5 -
0
a a 125
c
011
S
0
S a
;
40
S
0~
I
T
50 * a , . I - I I I I
0 2 4 6 8 10
b
nso
2100-
re s f i ai ; t
75
50 a X * . * . -u* * u-1
O 2 4 6 S 10
C
0 2 4 6 8 10
TotM bing tim (mm)
Flgwe 2 Relative RIF-l tumour and normal tissue perfusion
after breathing carbogen at 150 ml min-' for 1.5, 3.5, 5 or 8 min
before and during exposure to 'RbCI, i.e. for total times of 2.5,
4.5, 6 or 9min. Breathing at 150 mlminx is equivalent to 15 gas
exchanges per min. (a) Data for tumour (0) and skin (A), (b)
data for lung (0) and muscle (A) and (c) data for splen (-),
kidney (D) and liver (V). Data are pooled from two separate
experiments; n = 19-23 for tumour, sklin, muscle and lung and
15-18 for kidney, spleen and liver. Bars show ± 95% CL and the
hatched area shows the range of ± 95% CL for control animals
for tumour (a), lung (b) and kidney (c). Mean tumour volume
(±s.d.) was 515± 140mm3.Petuin iags it a-g and 'colinanide
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with the findings of Grau et al. (1992). who found no
changes in perfusion of the C3H mammary tumour located
in the foot. assayed by 'Rb extraction, for breathing times of
5-25 min. although these tumours did show increased
radiosensitivity with an enhancement ratio of 1.23. These
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Figure 3 Relative RIF-1 tumour and normal tissue perfusion
after 1000 mg kg nicotinamide (NCT) 60 mi previously or
nicotinamide combined with a total of 6 min carbogen breathing
(cbg) at 150 ml min or carbogen breathing alone. Breathing at
150 ml min-' is equivalent to 15 gas exchanges per min. (a) Data
for tumour (0) and skin (A), (b) shows data for lung (0) and
muscle (A) and (c) shows data for spleen (U). kidney (0) and
liver (v). Data are pooled from two separate experiments for
tumours (n = 22-24) and three experiments for normal tissues
(n = 31 -34). Bars show ± 95% CL and the hatched area shows
the range of ± 95% CL for control animals for tumour (a).
muscle (b) and kidney (c). Mean tumour volume (±s.d.) was
460±100. or 730±180mm.
authors attributed the radiosensitisation to the increased
oxygen content of the blood and reduction of chronic
hypoxia. The present data suggest that in some experimental
tumours part of a carbogen-induced increase in radiores-
ponse could be due to increased perfusion in addition to the
increased oxygen-carrying capacity of the blood. The conc-
lusion that perfusion changes in the RIF-I tumour are likely
to result in radiosensitisation is supported by the observation
that pentoxifylline. an agent which selectively increases
tumour perfusion at concentrations at which it has no direct
radiosensitising properties, is an effective radiosensitiser in
this tumour (Honess et al., 1993). The time courses of
radiosensitisation and of perfusion increase are closely cor-
related. and the magnitude of the perfusion increase is similar
to that found with carbogen. However, it would be impossi-
ble to demonstrate that a carbogen-induced perfusion in-
crease alone could cause radiosensitisation, since the per-
fusion effect cannot be separated from the increase in the
capacity of the blood to carry oxygen.
The changes in perfusion observed with carbogen breath-
ing were dependent on gas flow rate and also on breathing
time. Flow rates of 50-200 mlmnn- were almost equally
effective, but higher rates had progressively less effect (Figure
la) suggesting that some sort of compensation mechanism
came into play. At a fixed flow rate of 150 ml min'. it was
clear that the minimum time for increased perfusion was
4.5 min, but times longer than 11 min were not tested, so no
definite conclusion was reached on whether the increase
would be eliminated at longer breathing times. Previous
studies on the influence of preirradiation carbogen breathing
time on radiosensitisation in both KHT (Siemann et al.. 1977
and 1994) and SCCVII tumours (Chaplin et al.. 1993) have
shown that 5-30 min breathing gives maximum effect while
with much longer times. 60-120 mmn, radiosensitisation is
lost. In the CaNT tumour (Rojas et al. 1992) 5 min
breathing was the most effective of the range 2-20 min, but
all were beneficial, while Suit et al. (1972) found 15 min
much more effective than 0.5 mmn in the C3H mammary
tumour. The general finding for the time course for radiosen-
sitisation in these tumour systems is that a minimum of
5 min breathing is required for optimum radiosensitisation.
which is compatible with that required in the present work in
RIF-1 for an increase in perfusion. It therefore seems possi-
ble that a perfusion increase may contribute to the radiosen-
sitisation in these tumour models. However, in KHT and
SCCVII radiosensitisation is lost after 60 min of breathing
(Siemann et al., 1977, 1994: Chaplin et al.. 1993). while the
RIF-l data suggest that perfusion is reduced earlier than this
(Figure 2). A breathing time dependence of the improvement
in tumour oxygenation of clinical tumours. as measured by
Po2 distribution using microelectrodes, has also been
observed (Falk et al., 1992); the greatest improvement in
oxygenation was seen after 8- 12 min breathing and it
decreased as breathing continued. This suggests that similar
compensation mechanisms may be operating in human
tumours.
Relative perfusion changes caused by carbogen breathing
in tumour were larger than those observed in any other
tissue, but there was considerable variation between tumours.
The mean increase (±95% CL) over control caused by 6 min
at 150 ml min-' was 65 ± 12% (n = 76). There were small
increases in skin perfusion in some experiments (Figures 1
and 2) but not all (Figure 3). but these increases were
invariably much smaller than those in tumour. Owing to its
subcutaneous location, tumour would be expected to be
Table I Central tumour temperatures before and after nicotinamide and or carbogen treatment
Nicotinamide +
Control Nicotinamide carbogen Carbogen
Number of tumours 24 22 24 23
Temperature on entry 34.8 0.19 32.9 0.34 32.6 0.28 34.9 0.18
to jig (C) (±se.)
Temperature change during +0.10 0.15 0.00 0.17 +0.15 0.14 -0.12± 0.13
6 min in jig (± s.e.)
a van-
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influenced by changes in perfusion of the skin, its upstream
tissue, but since the tumour increases were so much larger
they cannot be secondary to changes in the skin, but must
constitute a genuine response of the tumour vasculature.
Apart from tumour, the only other tissue in which carbogen
had a substantial effect on perfusion was lung. These changes
are rather difficult to interpret. Lung tissue has a high blood
flow, with approximately 10% of the injected dose of 'Rb
being taken up per gram of tissue after a 60 s exposure.
compared with around 1-2% for both tumour and skin.
However. the observation does suggest that there was a
specific response in the lung. Kruuv et al. (1967) observed a
fall in respiration rate in anaesthetised animals breathing
carbogen, and it is possible that relative pulmonary flow may
be increased to compensate for this, or to eliminate the
increased carbon dioxide load. Respiration rate was not
measured in the current study.
The finding that mncotinamide caused no change in relative
tumour perfusion under the conditions employed was entirely
consistent with our earlier work, as was the noteworthy
increase in relative spleen perfusion (Honess and Bleehen.
1993). However. the RIF-I tumour is radiosensitised by
nicotinamide alone (Horsman et al.. 1987) and the likely
explanation for the apparent discrepancy between these
observations is that nicotinamide causes microregional
changes in perfusion which are not detected by 'Rb extrac-
tion, a volume-averaging technique, whereas carbogen
induces increases in global tumour perfusion which are
detected in this way. The relative tumour perfusion increases
after the combination of carbogen and nicotinamide (Figure
3a) can be attnrbuted to the effect of the carbogen alone,
which is not measurably changed by the presence of nico-
tinamide. In a closely related study we have measured the
effects of nicotinamide, carbogen and the combination under
conditions exactly similar to those used in the present work.
but measuring tumour Po, distribution with microelectrodes.
The finding was that control tumour oxygenation was very
little changed by nicotinamide. with 56% and 62% of
readings at <5 mmHg respectively, reflecting median values
of 4 mmHg in both situations. but was considerably im-
proved by carbogen breathing for 5 min at 150 ml min' to
18% of readings at <5 mmHg with a median of 15 mmHg
(P< 10' compared with control), and yet further improved
by the combination of 10% of readings at <5 mmHg with a
median of 28 mmHg (Honess et al.. 1995). indicating that an
additional oxygenation increase by nicotinamide may be
measured by this method (P< 10- for the combination
compared with carbogen alone).
There is a rapidly increasing body of data on the radiosen-
sitising properties of nicotinamide and carbogen in model
tumour and normal tissue systems. in both single dose and
fractionated regimens. From these studies it is becoming
apparent that there is considerable variation in the contribu-
tion of each treatment to that of the combination, depending
on the experimental system used. In some systems the addi-
tion of nicotinamide markedly increases the radioresponse
with carbogen where the effect of carbogen alone is small, for
example in rat spinal cord (Haustermans et al.. 1994). while
in other systems in which the effect of carbogen is much
larger the additional increase due to nicotinamide is relatively
small. for example in CaNT tumours (Rojas et al.. 1993a).
However, in the SCCVII tumour, in which both agents are
fairly effective, the combination is substantially more so
(Chaplin et al.. 1993). but in the KHT tumour. where each
agent individually has a greater effect than in SCCVII. the
combination is as effective as either agent alone (Siemann et
al.. 1994). In the RIF-1 tumour Donre et al.. (1994) have
shown that combined treatment is slightly more effective than
nicotinamide alone, but have no data for carbogen alone.
Clearly if a fully oxygenated radioresponse is generated by
one treatment alone, no additional treatment can provide
further benefit. but it is unlikely that this happens in all cases
with a single agent. One factor is that nicotinamide
treatments may not always have been optimally timed, most
investigators having given drug at all doses 60min before
irradiation. and it has recently been shown that the peak
drug concentration required for maximum radiosensitisation
occurs earlier than 60min for drug doses lower than
1000 mg kg-' (Horsman et al.. 1993). Nonetheless. these
reported variations in the contribution of each treatment are
also compatible with the existence of differences between
systems in terms of the ability of their vasculatures to res-
pond to the qualitatively different stimuli provided by car-
bogen and mncotinamide. If this is also true among human
tumours. it provides a further rationale, in addition to the
probable existence of both chronic and acute hypoxia. for the
superiority of the combination as a therapeutic tool over
either agent alone.
In summary. the present data show that in one tumour
system carbogen breathing can cause gross increases in
relative tumour perfusion. which are likely to improve
radioresponse by a mechanism in addition to the generally
accepted one of increasing the amount of oxygen carried in
the blood. When carbogen breathing is combined with
1000 mg kg- nicotinamide in the RIF-1 tumour at the
optimum time for radiosensitisation for this dose. there is no
further increase in relative perfusion. Since the combination
produces a greater improvement in tumour oxygenation than
carbogen alone (Honess et al.. 1995) and greater radiosen-
sitisation than nicotinamide alone (Dorie et al.. 1994) it
appears that the mechanisms of improvement in cellular
oxygenation by perfusion change by carbogen and
nicotinamide differ. A better understanding of these
mechanisms is required if these agents are to be employed
successfully in the optimisation of radiotherapy in the
clinic.
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